Miljöpåverkan
Palivizumab
Miljörisk:
Användning av aminosyror, proteiner och peptider bedöms inte medföra någon miljöpåverkan.
Läs mer
Detaljerad miljöinformation
Palivizumab is a human IgG1κ monoclonal antibody (mAb) directed to an epitope in the A antigenic site of the F-protein of RSV.
According to the European Medicines Agency guideline (Ref. 1) on environmental risk assessments for pharmaceuticals (EMA/CHMP/SWP/4447/00), vitamins, electrolytes, amino acids, peptides, proteins, carbohydrates, lipids, vaccines and herbal medicinal products are exempted because they are unlikely to result in significant risk to the environment.
This justifies the phrase:
Use of amino acids/peptides/proteins has been considered to result in insignificant environmental impact.
References
-
Committee for Medicinal Products for Human Use (CHMP). Guideline on the Environmental Risk Assessment of Medicinal Products for Human Use. EMEA/CPMP/SWP/4447/00 corr 2. 1 June 2006